WuXi Genome Center buys Illumina HiSeq X Ten sequencing system

Illumina, Inc. (NASDAQ:ILMN) and WuXi PharmaTech (Cayman) Inc. (NYSE:WX), a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company with operations in China and the United States, today announced that the WuXi Genome Center has purchased an Illumina HiSeq X Ten sequencing system.

This new investment will enable WuXi's clinical genomic services to expand from the current target panel, exome, and transcriptome scale sequencing to population genome scale sequencing. It puts the world's most advanced gene sequencing capability in the hands of the leading pharmaceutical R&D services company in the Asia Pacific region.

The WuXi Genome Center meets international clinical standards and is the only CLIA-certified clinical genomics lab in China. In addition to offering sequencing services, WuXi's genomics lab also provides assay development, validation, and testing services.

"This investment in cutting-edge gene sequencing technology significantly strengthens WuXi's broad, integrated platform of R&D services," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "It advances our mission of enabling anyone and any company to use our R&D platform to discover and develop innovative medicines to benefit the world's patients."

The HiSeq X Ten is the world's first platform to deliver full coverage human genomes for $1,000, including typical instrument depreciation, DNA extraction, library preparation, and estimated labor. Purpose-built for population-scale human whole genome sequencing, the HiSeq X Ten can sequence approximately 18,000 samples annually with high-quality, high-coverage sequencing. It is sold as a set of 10 or more ultra-high throughput sequencing systems, each generating up to 1.8 terabases (Tb) of sequencing data in less than three days or up to 600 gigabases (Gb) per day, per system.

"We are pleased that WuXi has chosen the HiSeq X Ten to serve its clients with state-of-the-art gene sequencing capabilities," said Jay Flatley, CEO of Illumina. "Illumina's leadership in the development of genomics technologies and WuXi's leadership in offering high-quality R&D services to leading biopharmaceutical companies are a perfect fit."

Source:

Illumina, Inc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Illumina, Inc.. (2019, June 18). WuXi Genome Center buys Illumina HiSeq X Ten sequencing system. News-Medical. Retrieved on November 29, 2022 from https://www.news-medical.net/news/20140310/WuXi-Genome-Center-buys-Illumina-HiSeq-X-Ten-sequencing-system.aspx.

  • MLA

    Illumina, Inc.. "WuXi Genome Center buys Illumina HiSeq X Ten sequencing system". News-Medical. 29 November 2022. <https://www.news-medical.net/news/20140310/WuXi-Genome-Center-buys-Illumina-HiSeq-X-Ten-sequencing-system.aspx>.

  • Chicago

    Illumina, Inc.. "WuXi Genome Center buys Illumina HiSeq X Ten sequencing system". News-Medical. https://www.news-medical.net/news/20140310/WuXi-Genome-Center-buys-Illumina-HiSeq-X-Ten-sequencing-system.aspx. (accessed November 29, 2022).

  • Harvard

    Illumina, Inc.. 2019. WuXi Genome Center buys Illumina HiSeq X Ten sequencing system. News-Medical, viewed 29 November 2022, https://www.news-medical.net/news/20140310/WuXi-Genome-Center-buys-Illumina-HiSeq-X-Ten-sequencing-system.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Illumina donates more than 95,000 human genetic variants to ClinVar database